A study to compare whether there is a difference in the improvement of swallowing function between two types of anti-gastric ulcer drugs for elderly people with a history of gastric ulcer and dysphagia.

INTERVENTION: Institutional elderly people aged 65 and over with a history of gastric ulcer who have dysphagia are divided into two groups, and each group received 150 mg/day of polaprezinc tablet or 300 mg/day of rebamipide tablet for two months. After that, the gastric ulcer therapeutic agents in both groups is exchanged, and the subjects are asked to take it again for two months. CONDITION: D003680 Swallowing dysfunction Gastric ulcer ; Swallowing dysfunction, Elderly People Swallowing dysfunction, Elderly People PRIMARY OUTCOME: Improvement of swallowing reflex induction rate by taking a zinc‐containing gastric ulcer drug or a non‐zinc‐containing gastric ulcer drug. SECONDARY OUTCOME: 1. Including cases that dropped out without performing 3 measurements of the simple swallowing provocation test, comparison of the amount of change in swallowing refle Xinduction time.; 2.Comparison of the number of cases with improved swallowing refle Xinduction time.; 3. Improvement of ADL and sarcopenia, gait status, score, and muscle mass.; 4. Improvement of nutritional items in blood and biochemical tests.; 5. Difference in increase in serum zinc concentration due to concomitant drugs, difference in the number of people who improved.; 6. Difference in serum zinc concentration increase due to comorbidities, difference in the number of people who improved.; 7. Changes in serum zinc concentration and substance P in blood and saliva.; 8. Confirmation of the safety of administration of two gastric ulcer drugs to patients with dysphagia. INCLUSION CRITERIA: Elderly people aged 65 years or older with a history of gastric ulcer who have subjective symptoms of swallowing dysfunction or who have been diagnosed with swallowing dysfunction, and who are taking antacids.